Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biopharmaceutical company developing engineered regulatory T cell (Treg) therapies to restore immune balance in autoimmune and inflammatory diseases. Building on Nobel Prize-winning Treg biology, its lead program SBT-77-7101 is in Phase 1 clinical trials for conditions including refractory rheumatoid arthritis and hidradenitis suppurativa. Backed by 8VC and GV, the company operates in cell therapy and does not publish a public developer API surface. Sector: biotech.
Sonoma Biotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Cell Therapy, Immunology, and Autoimmune.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API